Zusammenfassung
Die Behandlung von Persönlichkeits- und Verhaltensstörungen ist zur Domäne der Psychotherapie geworden. Gleichwohl hat die Psychopharmakotherapie insbesondere im Klinikalltag einen hohen Stellenwert. Einige Verhaltensstörungen werden aufgrund der neuen DSM-5- und ICD11-Strukturen in anderen Kapiteln besprochen, z. B. die Verhaltenssüchte in Kapitel 7.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Ballester-Arnal R, Castro-Calvo J, Giménez-García C et al (2020) Psychiatric comorbidity in compulsive sexual behavior disorder (CSBD). Addict Behav 107:106384
Bellino S, Bozzatello P, Rocca G et al (2014) Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 28:125–132
Bertsch K, Herpertz SC (2018) Oxytocin and borderline personality disorder. Curr Top Behav Neurosci 35:499–514
Black DW, Zanarini MC, Romine A et al (2014) Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 171:1174–1182
Bozzatello P, Brignolo E, De Grandi E, Bellino S (2016) Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med 5(8):E67
Bozzatello P, Rocca P, Bellino S (2018) Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study. Clin Drug Investig 38(4):367–372
Bridler R, Häberle A, Müller ST et al (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25:763–772
Costa AM, Medeiros GC, Redden S et al (2018) Cognitive-behavioral group therapy for intermittent explosive disorder: description and preliminary analysis. Rev Bras Psiquiatr 40(3):316–319
Crawford MJ, Sanatinia R, Barrett B et al; LABILE study team (2018) The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry 175(8):756–764
Cristea IA, Gentili C, Cotet CD et al (2017) Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry 74(4):319–328
Farde L, Plavén-Sigray P, Borg J, Cervenka S (2018) Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 373(1744):20170156
Gunderson JG, Herpertz SC, Skodol AE et al (2018) Borderline personality disorder. Nat Rev Dis Primers 4:18029
Hancock-Johnson E, Griffiths C, Picchioni M (2017) A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs 31(5):345–356
Herpertz SC (2018) Neue Wege der Klassifikation von Persönlichkeitsstörungen in ICD-11. Fortschr Neurol Psychiatr 86(03):150–155
Hill N, Geoghegan M, Shawe-Taylor M (2016) Evaluating the outcomes of the STEPPS programme in a UK community-based population; implications for the multidisciplinary treatment of borderline personality disorder. J Psychiatr Ment Health Nurs 23:347–356
Ingenhoven T, Lafay P, Rinne T et al (2010) Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 71:14–25
Ingenhoven TJ, Duivenvoorden HJ (2011) Differential effectiveness of antipsychotics in borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical trials on symptomatic outcome domains. J Clin Psychopharmacol 31(4):489–496
Krüger TH, Magid M, Wollmer MA (2016) Can botulinum toxin help patients with borderline personality disorder? Am J Psychiatry 173(9):940–941
Lischke A, Herpertz SC, Berger C (2017) Divergent effects of oxytocin on (para-)limbic reactivity to emotional and neutral scenes in females with and without borderline personality disorder. Soc Cogn Affect Neurosci 12(11):1783–1792
Martín-Blanco A, Patrizi B, Soler J et al (2017a) Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report. Int Clin Psychopharmacol 32(4):231–234
Martín-Blanco A, Ancochea A, Soler J et al (2017b) Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand 136(3):323–331
McCabe GA, Widiger TA (2020) A comprehensive comparison of the ICD-11 and DSM-5 section III personality disorder models. Psychol Assess 32:72–84
Mielke EL, Neukel C, Bertsch K et al (2018) Alterations of brain volumes in women with early life maltreatment and their associations with oxytocin. Horm Behav 97:128–136
Naguy A, Al-Enezi N (2019) Lamotrigine uses in psychiatric practice. Am J Ther 6(1):e96–e102
Pérez-Pérez B, Cristóbal-Narváez P, Sheinbaum T et al (2018) Interaction between FKBP5 variability and recent life events in the anxiety spectrum: evidence for the differential susceptibility model. PLoS ONE 13(2):e193044
Simonsen S, Bateman A, Bohus M et al (2019) European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregul 6:9
Stoffers J, Völlm BA, Rücker G et al (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005653.pub2
Stoffers-Winterling J, Lieb K (2015) Pharmakotherapie von Borderline-Persönlichkeitsstörungen – Versorgungsalltag versus aktuelle externe Evidenz. Info Neurol Psychiatr 17:51–55
Tebartz van Elst L, Fleck M, Bartels S et al (2016) Increased prevalence of intermittent rhythmic delta or theta activity (IRDA/IRTA) in the electroencephalograms (EEGs) of patients with borderline personality disorder. Front Behav Neurosci 10:12
Timäus C, Meiser M, Bandelow B et al (2019) Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC Psychiatry 19:393
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Müller, M.J., Benkert, O. (2021). Medikamente zur Behandlung von Persönlichkeits- und Verhaltensstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-61753-3_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-61752-6
Online ISBN: 978-3-662-61753-3
eBook Packages: Medicine (German Language)